Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM)
Authors not listed
University of Cincinnati · 2011
Abstract
The purpose of this study is to determine whether the addition of an investigational medication, axitinib, to radiation therapy will improve the outcome of treatment in patients, above the age of 70.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2011). A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM). <em>University of Cincinnati</em>. https://clinicaltrials.gov/study/NCT01508117
Vancouver
Anonymous. A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM). University of Cincinnati. 2011.
BibTeX
@misc{anon2011APhase,
title = {A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM)},
author = {Anonymous},
journal = {University of Cincinnati},
year = {2011},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
New York State Psychiatric Institute 2004
Open access · US-GOV
Antipsychotic Discontinuation in Alzheimer's Disease
Prof. Dr. Med. Laimonas Griskevicius 2011
Open access · US-GOV
Study of Rituximab in Addition to Glucocorticoid in Pretreated Elderly or Unfit Patients With Chronic B Lymphocytic Leukemia
Sunnybrook Health Sciences Centre 2014
Open access · US-GOV
A Phase I/II Trial of Ruxolitinib (Jakafi) in Patients With Chronic Lymphocytic Leukemia Who Are Unfit for Conventional First-line Therapy Due to Age or 17p Deletions
Fondazione EMN Italy Onlus 2008
Open access · US-GOV
A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus 2006
Open access · US-GOV
A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS
Rishi Singh 2012
Open access · US-GOV